SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001013762-23-003163
Filing Date
2023-10-11
Accepted
2023-10-11 16:10:32
Documents
12
Period of Report
2023-10-10
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea186627-8k_virpaxpharma.htm   iXBRL 8-K 27250
  Complete submission text file 0001013762-23-003163.txt   202673

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vrpx-20231010.xsd EX-101.SCH 3027
3 XBRL LABEL FILE vrpx-20231010_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE vrpx-20231010_pre.xml EX-101.PRE 22367
6 EXTRACTED XBRL INSTANCE DOCUMENT ea186627-8k_virpaxpharma_htm.xml XML 3427
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 231320820
SIC: 2834 Pharmaceutical Preparations